Physician profile
Darryl C Johnson
NPI 1720084916
$943.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $141 · 2021: $293 · 2022: $223 · 2023: $16.74 · 2024: $20.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $191.40 | 2019-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $174.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.05 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.12 | 2019-2022 | |
| Novo Nordisk INC | $57.61 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $57.61 | 2019 | |
| Abbvie INC. | $48.91 | 2020 | |
| Lilly USA, LLC | $24.68 | 2021-2022 | |
| Hologic Sales and Service, LLC | $20.50 | 2024 | Myosure Tissue Removal Device |
| Urovant Sciences INC | $19.60 | 2022 | |
| Amarin Pharma, INC. | $18.84 | 2021 | |
| Exeltis, USA INC. | $17.89 | 2020 | |
| Amgen INC. | $17.59 | 2021 | |
| Merck Sharp & Dohme LLC | $14.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.61 | 2019 | |
| Eisai INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.